Skip to main content

Advertisement

Table 1 Vascular endothelial growth facto levels, central macular thickness, and best-corrected visual acuity before and after intravitreal injection of bevacizumab in neovascular age macular degeneration

From: Aqueous vascular endothelial growth factor and clinical outcomes correlation after single intravitreal injection of bevacizumab in patients with neovascular age-related macular degeneration

  Baseline 7d 30d 3 m
VEGF (pg/mL) 179.7 ± 88.369 44.2 ± 25.258 56.6 ± 17.788 84.4 ± 23.378
   P < 0.0001 P < 0.0001 P < 0.0001
BCVA (decimal) 0.044 ± 0.062 0.079 ± 0.079 0.102 ± 0.085 0.084 ± 0.075
   P 0.0020 P < 0.0001 P 0.0005
SD-OCT
 CRT (μm) 407.0 ± 190.374 307.9 ± 94.128 294.8 ± 104.173 334.3 ± 104.904
   P 0.0018 P 0.0005 P 0.0198
 MV (mm3) 11.992 ± 3.740 10.700 ± 2.325 10.338 ± 2.286 10.867 ± 2.290
   P 0.0346 P 0.0074 P 0.0647
 MA (μm) 332.5 ± 104.318 297.7 ± 64.979 287.4 ± 63.545 299.6 ± 65.462
   P 0.0420 P 0.0091 P 0.0543
  1. VEGF vascular endothelial growth factor, BCVA best-corrected visual acuity, SD-OCT spectral-domain optical coherence tomography, CRT central retinal thickness, MV macular volume, MA macular area, P P value (comparisons with baseline)
  2. * Linear mixed models were used to compare time points